The transforming growth factor-b (TGF-b) pathway plays dual roles in cancer, inhibiting epithelial cell growth under normal physiologic conditions, but promoting invasion and metastasis once growth inhibitory responses are lost. Two recent papers show that TGF-b receptor III is the most common TGF-b pathway component downregulated in prostate cancer. Here, we discuss the implications of these findings and what it may mean about the biology of this disease.
Text
One of the six hallmarks of cancer proposed by Hanahan & Weinberg (2000) is an acquired insensitivity to inhibitors of cell growth. Transforming growth factor-b (TGF-b) is probably the best-characterized antigrowth pathway. Acquired resistance to growth inhibition induced by TGF-b signaling is a characteristic of the early stages of many solid tumors (Elliott & Blobe 2005) . The canonical TGF-b pathway involves the heterodimerization of TGF-b receptor I (TGFbRI) and TGFbRII, followed by phosphorylation and activation of TGFbRI by TGFbRII. A third receptor, TGFbRIII, is involved in TGF-b signaling, with a function that is not well defined and will be discussed further later. Once activated by TGFbRII, TGFbRI phosphorylates SMAD2 and SMAD3 (the receptor SMADs or R-SMADs) and these phosphorylated R-SMADs associate with the common SMAD, SMAD4. The phosphorylated R-SMAD/SMAD4 complex is retained in the nucleus, where it regulates the transcription of TGF-b responsive genes (Shi & Massague 2003) .
Accordingly, resistance to TGF-b signaling is mediated by perturbations in various members of this pathway. The mechanisms of resistance in many solid tumors are well defined. For example, mutations in TGFbRII are frequently found in colon cancer (Grady et al. 1999) and SMAD4 deletions are found in pancreatic tumors (Hahn et al. 1996) . In prostate cancer, loss of TGFbRI or TGFbRII expression is found in about 30% of cases (Kim et al. 1996 , Guo et al. 1997 , but the mechanism of TGF-b resistance in the majority of prostate cancers remained undefined. This prompted two recent studies of TGFbRIII in prostate cancer, both of which suggest that loss of TGFbRIII expression is the most commonly perturbed TGF-b pathway component in prostate cancer (Sharifi et al. 2007 , Turley et al. 2007 ). Sharifi et al. (2007) sought to address changes in the expression of TGF-b pathway components in prostate cancer. Using Oncomine, a freely available web-based database of DNA microarray studies of various malignancies (Rhodes et al. 2004) , they found that TGFbRIII is the most commonly downregulated TGF-b component across seven DNA microarray studies of benign prostate versus localized prostate cancer. Then, TGFbRIII mRNA was also found to be downregulated in the majority of prostate cancer cell lines tested. To determine if TGFbRIII downregulation might play a role in development of prostate intraepithelial neoplasia (PIN), a precursor to invasive prostate cancer, the effect of TGFbRIII downregulation on markers of carcinogenesis was evaluated. These studies showed that TGFbRIII levels had significant effects on vimentin expression. shRNA knockdown of TGFbRIII in noncancerous prostate epithelial cells leads to downregulation of vimentin mRNA and protein loss, indicating that TGFbRIII controls vimentin expression. This is significant because vimentin expression is decreased in the transition from benign prostate to local prostate cancer in the majority of DNA microarray studies in Oncomine, and previously published findings show that vimentin protein is expressed in benign prostate and lost in prostate cancer and PIN (Nagle et al. 1991) . Since vimentin expression is lost as early as PIN and is dependent on TGFbRIII for expression, it follows that TGFbRIII may be lost as early as PIN. This hypothesis was confirmed in another set of studies by Turley et al. (2007) who examined TGFbRIII protein by immunohistochemistry and showed decreased expression in clinical prostate cancer specimens. Loss of TGFbRIII at the mRNA level was confirmed using Oncomine. Furthermore, it was found that the protein is downregulated in the transition from benign prostate to high-grade PIN and that TGFbRIII loss occurs continuously throughout progression of prostate cancer.
These two studies also reveal the phenotypic and genetic consequences of TGFbRIII expression. Sharifi et al. (2007) showed that shRNA knockdown of TGFbRIII in an immortalized prostate epithelial cell line causes focus formation, increased cell surface expression of a prostate stem cell marker and downregulation of one of the most potent inhibitors of angiogenesis, SERPINF1 (also known as pigment epithelium derived growth factor; Doll et al. 2003) . Turley et al. (2007) reexpressed TGFbRIII in a prostate cancer cell line that had lost expression, and showed decreased cell migration, invasiveness and tumorigenicity. Together, these studies strongly support a role for TGFbRIII as a tumor suppressor in prostate cancer.
Despite the findings of TGFbRIII downregulation and characterization of phenotypic changes that correlate with TGFbRIII expression, the exact function of TGFbRIII in the prostate remains unclear. TGFbRIII can affect prostate epithelial signaling through at least four mechanisms. First, TGFbRIII acts as a coreceptor and enhances TGF-b signaling by augmenting ligand binding to TGFbRII (Wang et al. 1991) . This function would support the role of TGFbRIII loss as a means of resistance to the canonical TGF-b pathway early in prostate tumorigenesis. Second, involves the role of the soluble form of TGFbRIII. Soluble TGFbRIII is formed by proteolytic cleavage of the extracellular domain and can antagonize TGF-b function by TGF-b ligand sequestration (Lopez-Casillas et al. 1994) . In this scenario, loss of TGFbRIII would lead to an increase in TGF-b signaling, and increased inhibitory responses in the absence of other pathway perturbations. Third, is the possibility that TGFbRIII may function in a noncanonical pathway. TGFbRIII can interact with Ga-interacting proteins and b-arrestins (Turley et al. 2007 ). This supports a signaling role that may be Figure 1 TGFbRIII loss in the prostate could lead to resistance to testicular inhibin B. TGFbRIII is a tumor suppressor in the prostate and functions as a receptor for inhibin B. TGFbRIII is also downregulated in localized prostate cancer as early as prostate intraepithelial neoplasia. The tumor-suppressive properties of TGFbRIII may be linked to its role in responding to inhibin B. independent of the SMADs. It is possible that this pathway is necessary for growth inhibitory responses or maintenance of normal tissue architecture.
A fourth and very interesting possibility, however, is that TGFbRIII downregulation plays an altogether different role in the prostate. In addition to acting as a coreceptor for TGF-b ligands, TGFbRIII is also a receptor for and tightly binds inhibins, which are TGF-b superfamily cytokines that have antagonistic actions to activins (Lewis et al. 2000) . In most systems studied, activins have similar properties to TGF-b and signal through the same SMAD pathway (Massague et al. 2005) . The antagonistic property of inhibin has to do with inhibin binding the type II activin receptor and TGFbRIII, forming a complex that interferes with activin binding the type II receptor, thereby inhibiting signal transduction. Although inhibins are mechanistically antagonistic to activin-mediated signal transduction, a signaling mechanism for inhibins that does not involve activin antagonism has not been ruled out. Whatever the function of inhibins may be downstream of TGFbRIII, this may have hormonal and physiological implications for prostate biology.
Inhibins have an important role in male reproduction and reproductive organs (O'Connor & De Kretser 2004) . Inhibin B is secreted by the testes, found in circulating blood, and correlates with male fertility. The following model that we propose is of a role for TGFbRIII and inhibin B in prostate biology that is antagonistic and may be physiologically complementary to the role of androgens. Androgens produced by the testes stimulate the growth of prostate cancer cells and androgen deprivation reverses this growth stimulation (Sharifi et al. 2005) . Androgens are also involved in stimulating the development of PIN and early prostate tumorigenesis (Tomlins et al. 2007 ). Inhibins may act as a negative regulator of prostate growth, in which case TGFbRIII downregulation in prostate cancer may represent resistance to testicular inhibin B (Fig. 1) . Furthermore, male inhibin-a subunit knockout mice form tumors in both testes and adrenal glands (Matzuk et al. 1992 (Matzuk et al. , 1994 , which may reflect loss of feedback inhibition on these organs. If gonadal inhibin is a prostate tumor suppressor, prostate cancer may be expected from inhibin knockout mice. However, these mice die of gonadal stromal tumors. To allow prolonged survival, inhibin knockout mice had to be gonadectomized and the consequent loss of this major source of androgens may explain why prostate tumors were not observed. It may also be physiologically relevant that both of the organs -testes and adrenals -that produce androgens and inhibins, form tumors when inhibin is knocked out in mouse. Together, these data combined with the observation of TGFbRIII downregulation in prostate cancer suggest that there may be a role for inhibin-mediated tumor suppression in prostate. Inhibins have had a controversial role in prostate cancer where its expression has been studied mainly in prostate tissue (Ball et al. 2004) ; it may be that the relevant perturbation in signaling had not been described prior to these two studies of TGFbRIII in the prostate. If TGFbRIII downregulation in prostate cancer signifies inhibin resistance, it may open a new window on hormonal physiology and an interplay between hormones and cancer.
